| Title: |
Circulating free insulin-like growth factor-I and prostate cancer: a case-control study nested in the European prospective investigation into cancer and nutrition |
| Authors: |
Cheng, TS; Noor, U; Watts, E; Pollak, M; Wang, Y; McKay, J; Atkins, J; Masala, G; Sánchez, M; Agudo, A; Castilla, J; Aune, D; Colorado-Yohar, SM; Manfredi, L; Gunter, MJ; Pala, V; Josefsson, A; Key, TJ; Smith-Byrne, K; Travis, RC |
| Publisher Information: |
BioMed Central |
| Publication Year: |
2024 |
| Collection: |
Oxford University Research Archive (ORA) |
| Description: |
Background: Circulating total insulin-like growth factor-I (IGF-I) is an established risk factor for prostate cancer. However, only a small proportion of circulating IGF-I is free or readily dissociable from IGF-binding proteins (its bioavailable form), and few studies have investigated the association of circulating free IGF-I with prostate cancer risk. Methods: We analyzed data from 767 prostate cancer cases and 767 matched controls nested within the European Prospective Investigation into Cancer and Nutrition cohort, with an average of 14-years (interquartile range = 2.9) follow-up. Matching variables were study center, length of follow-up, age, and time of day and fasting duration at blood collection. Circulating free IGF-I concentration was measured in serum samples collected at recruitment visit (mean age 55 years old; standard deviation = 7.1) using an enzyme-linked immunosorbent assay (ELISA). Conditional logistic regressions were performed to examine the associations of free IGF-I with risk of prostate cancer overall and subdivided by time to diagnosis (≤ 14 and > 14 years), and tumor characteristics. Results: Circulating free IGF-I concentrations (in fourths and as a continuous variable) were not associated with prostate cancer risk overall (odds ratio [OR] = 1.00 per 0.1 nmol/L increment, 95% CI: 0.99, 1.02) or by time to diagnosis, or with prostate cancer subtypes, including tumor stage and histological grade. Conclusions: Estimated circulating free IGF-I was not associated with prostate cancer risk. Further research may consider other assay methods that estimate bioavailable IGF-I to provide more insight into the well-substantiated association between circulating total IGF-I and subsequent prostate cancer risk. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1186/s12885-023-11425-w |
| Availability: |
https://doi.org/10.1186/s12885-023-11425-w; https://ora.ox.ac.uk/objects/uuid:916da959-bae3-477c-8fce-7434cb9e7480 |
| Rights: |
info:eu-repo/semantics/openAccess ; CC Attribution (CC BY) |
| Accession Number: |
edsbas.7FC21EFE |
| Database: |
BASE |